Nektar Therapeutics (0UNL.L)
USD 0.84
(0.63%)
USD 0.84
(0.63%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 190.9 Million USD | -38.55% |
| 2022 | 310.65 Million USD | -40.61% |
| 2021 | 523.11 Million USD | 1.9% |
| 2020 | 513.36 Million USD | -3.74% |
| 2019 | 533.27 Million USD | 10.87% |
| 2018 | 480.97 Million USD | 49.92% |
| 2017 | 320.82 Million USD | 29.33% |
| 2016 | 248.07 Million USD | 9.74% |
| 2015 | 226.05 Million USD | 19.82% |
| 2014 | 188.65 Million USD | -18.17% |
| 2013 | 230.54 Million USD | 21.15% |
| 2012 | 190.28 Million USD | 9.66% |
| 2011 | 173.52 Million USD | 16.42% |
| 2010 | 149.05 Million USD | 9.5% |
| 2009 | 136.11 Million USD | -1.22% |
| 2008 | 137.8 Million USD | -14.76% |
| 2007 | 161.65 Million USD | -37.55% |
| 2006 | 258.85 Million USD | -2.34% |
| 2005 | 265.05 Million USD | 57.38% |
| 2004 | 168.41 Million USD | 6.75% |
| 2003 | 157.76 Million USD | -16.04% |
| 2002 | 187.9 Million USD | 2.12% |
| 2001 | 184 Million USD | 59.34% |
| 2000 | 115.47 Million USD | 60.49% |
| 1999 | 71.95 Million USD | 64.33% |
| 1998 | 43.78 Million USD | 46.08% |
| 1997 | 29.97 Million USD | 52.92% |
| 1996 | 19.6 Million USD | 47.37% |
| 1995 | 13.3 Million USD | 68.35% |
| 1994 | 7.9 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 50.23 Million USD | 5.63% |
| 2024 Q1 | 47.55 Million USD | 0.62% |
| 2023 FY | 190.9 Million USD | -38.55% |
| 2023 Q1 | 51.55 Million USD | -9.05% |
| 2023 Q2 | 47.55 Million USD | -7.76% |
| 2023 Q3 | 45.21 Million USD | -4.91% |
| 2023 Q4 | 47.26 Million USD | 4.52% |
| 2022 Q2 | 63.26 Million USD | -53.0% |
| 2022 Q1 | 134.59 Million USD | 2.15% |
| 2022 FY | 310.65 Million USD | -40.61% |
| 2022 Q4 | 56.67 Million USD | 0.99% |
| 2022 Q3 | 56.12 Million USD | -11.28% |
| 2021 Q1 | 127.28 Million USD | -1.98% |
| 2021 Q2 | 130.86 Million USD | 2.82% |
| 2021 FY | 523.11 Million USD | 1.9% |
| 2021 Q3 | 133.2 Million USD | 1.79% |
| 2021 Q4 | 131.75 Million USD | -1.09% |
| 2020 Q3 | 127.51 Million USD | 5.57% |
| 2020 Q2 | 120.78 Million USD | -10.67% |
| 2020 FY | 513.36 Million USD | -3.74% |
| 2020 Q4 | 129.86 Million USD | 1.84% |
| 2020 Q1 | 135.2 Million USD | -1.68% |
| 2019 Q3 | 123.03 Million USD | -4.82% |
| 2019 Q1 | 143.46 Million USD | 8.15% |
| 2019 FY | 533.27 Million USD | 10.87% |
| 2019 Q4 | 137.51 Million USD | 11.77% |
| 2019 Q2 | 129.26 Million USD | -9.9% |
| 2018 Q4 | 132.66 Million USD | 9.08% |
| 2018 Q3 | 121.61 Million USD | 11.99% |
| 2018 FY | 480.97 Million USD | 49.92% |
| 2018 Q2 | 108.59 Million USD | -8.06% |
| 2018 Q1 | 118.11 Million USD | 25.96% |
| 2017 Q3 | 77.76 Million USD | 1.98% |
| 2017 Q1 | 73.03 Million USD | 15.94% |
| 2017 Q2 | 76.25 Million USD | 4.41% |
| 2017 Q4 | 93.76 Million USD | 20.57% |
| 2017 FY | 320.82 Million USD | 29.33% |
| 2016 Q4 | 62.99 Million USD | 1.27% |
| 2016 FY | 248.07 Million USD | 9.74% |
| 2016 Q2 | 63.38 Million USD | 6.54% |
| 2016 Q1 | 59.49 Million USD | -1.45% |
| 2016 Q3 | 62.2 Million USD | -1.86% |
| 2015 Q3 | 52.77 Million USD | -5.08% |
| 2015 FY | 226.05 Million USD | 19.82% |
| 2015 Q2 | 55.59 Million USD | -3.0% |
| 2015 Q1 | 57.31 Million USD | 12.95% |
| 2015 Q4 | 60.37 Million USD | 14.4% |
| 2014 Q1 | 48.26 Million USD | -16.9% |
| 2014 Q2 | 46.32 Million USD | -4.03% |
| 2014 Q3 | 43.33 Million USD | -6.46% |
| 2014 Q4 | 50.74 Million USD | 17.1% |
| 2014 FY | 188.65 Million USD | -18.17% |
| 2013 Q1 | 56.74 Million USD | -0.86% |
| 2013 FY | 230.54 Million USD | 21.15% |
| 2013 Q4 | 58.08 Million USD | 6.46% |
| 2013 Q3 | 54.55 Million USD | -11.23% |
| 2013 Q2 | 61.45 Million USD | 8.3% |
| 2012 Q3 | 44.08 Million USD | 1.41% |
| 2012 Q4 | 57.23 Million USD | 29.84% |
| 2012 Q1 | 45.49 Million USD | 1.56% |
| 2012 Q2 | 43.46 Million USD | -4.46% |
| 2012 FY | 190.28 Million USD | 9.66% |
| 2011 Q2 | 43.45 Million USD | 3.7% |
| 2011 FY | 173.52 Million USD | 16.42% |
| 2011 Q4 | 44.8 Million USD | 3.3% |
| 2011 Q3 | 43.36 Million USD | -0.2% |
| 2011 Q1 | 41.9 Million USD | -2.64% |
| 2010 Q4 | 43.04 Million USD | 13.55% |
| 2010 Q1 | 32.29 Million USD | -6.59% |
| 2010 FY | 149.05 Million USD | 9.5% |
| 2010 Q2 | 35.8 Million USD | 10.86% |
| 2010 Q3 | 37.9 Million USD | 5.86% |
| 2009 Q1 | 34.91 Million USD | 487.93% |
| 2009 Q4 | 34.57 Million USD | 3.55% |
| 2009 Q3 | 33.39 Million USD | 0.46% |
| 2009 FY | 136.11 Million USD | -1.22% |
| 2009 Q2 | 33.23 Million USD | -4.79% |
| 2008 Q1 | 49.31 Million USD | 1035.34% |
| 2008 FY | 137.8 Million USD | -14.76% |
| 2008 Q4 | -8.99 Million USD | -117.77% |
| 2008 Q3 | 50.65 Million USD | 8.16% |
| 2008 Q2 | 46.82 Million USD | -5.05% |
| 2007 Q1 | 54.46 Million USD | -20.98% |
| 2007 FY | 161.65 Million USD | -37.55% |
| 2007 Q4 | 4.34 Million USD | -91.03% |
| 2007 Q3 | 48.43 Million USD | -10.99% |
| 2007 Q2 | 54.41 Million USD | -0.09% |
| 2006 FY | 258.85 Million USD | -2.34% |
| 2006 Q1 | 53.13 Million USD | -56.66% |
| 2006 Q2 | 86.66 Million USD | 63.09% |
| 2006 Q4 | 68.92 Million USD | 37.48% |
| 2006 Q3 | 50.13 Million USD | -42.15% |
| 2005 FY | 265.05 Million USD | 57.38% |
| 2005 Q4 | 122.59 Million USD | 142.67% |
| 2005 Q2 | 46.9 Million USD | -0.91% |
| 2005 Q1 | 47.33 Million USD | 10.14% |
| 2005 Q3 | 50.52 Million USD | 7.72% |
| 2004 Q2 | 42.91 Million USD | 8.85% |
| 2004 Q3 | 43.1 Million USD | 0.45% |
| 2004 FY | 168.41 Million USD | 6.75% |
| 2004 Q4 | 42.97 Million USD | -0.31% |
| 2004 Q1 | 39.42 Million USD | -7.73% |
| 2003 Q3 | 37.94 Million USD | -1.8% |
| 2003 Q2 | 38.64 Million USD | 0.51% |
| 2003 FY | 157.76 Million USD | -16.04% |
| 2003 Q4 | 42.72 Million USD | 12.59% |
| 2003 Q1 | 38.44 Million USD | -23.65% |
| 2002 FY | 187.9 Million USD | 2.12% |
| 2002 Q4 | 50.35 Million USD | 9.8% |
| 2002 Q3 | 45.86 Million USD | 6.03% |
| 2002 Q2 | 43.25 Million USD | -10.7% |
| 2002 Q1 | 48.43 Million USD | -11.59% |
| 2001 Q3 | 48.91 Million USD | 13.93% |
| 2001 Q1 | 37.36 Million USD | 20.61% |
| 2001 FY | 184 Million USD | 59.34% |
| 2001 Q2 | 42.93 Million USD | 14.9% |
| 2001 Q4 | 54.78 Million USD | 11.99% |
| 2000 Q1 | 25.4 Million USD | 9.67% |
| 2000 FY | 115.47 Million USD | 60.49% |
| 2000 Q3 | 29.99 Million USD | 3.12% |
| 2000 Q4 | 30.98 Million USD | 3.28% |
| 2000 Q2 | 29.09 Million USD | 14.51% |
| 1999 Q4 | 23.16 Million USD | 26.86% |
| 1999 Q3 | 18.26 Million USD | 10.37% |
| 1999 FY | 71.95 Million USD | 64.33% |
| 1999 Q2 | 16.54 Million USD | 18.35% |
| 1999 Q1 | 13.98 Million USD | 5.8% |
| 1998 Q4 | 13.21 Million USD | 22.8% |
| 1998 Q3 | 10.76 Million USD | 0.84% |
| 1998 Q2 | 10.67 Million USD | 16.71% |
| 1998 FY | 43.78 Million USD | 46.08% |
| 1998 Q1 | 9.14 Million USD | 0.58% |
| 1997 Q1 | 5.92 Million USD | -17.76% |
| 1997 Q3 | 7.77 Million USD | 8.53% |
| 1997 Q4 | 9.08 Million USD | 16.95% |
| 1997 FY | 29.97 Million USD | 52.92% |
| 1997 Q2 | 7.16 Million USD | 20.94% |
| 1996 Q3 | 4.5 Million USD | 2.27% |
| 1996 Q4 | 7.2 Million USD | 60.0% |
| 1996 Q1 | 3.6 Million USD | -18.18% |
| 1996 FY | 19.6 Million USD | 47.37% |
| 1996 Q2 | 4.4 Million USD | 22.22% |
| 1995 Q1 | 2.9 Million USD | -55.38% |
| 1995 Q2 | 3 Million USD | 3.45% |
| 1995 Q4 | 4.4 Million USD | 46.67% |
| 1995 Q3 | 3 Million USD | 0.0% |
| 1995 FY | 13.3 Million USD | 68.35% |
| 1994 Q1 | 400 Thousand USD | 0.0% |
| 1994 FY | 7.9 Million USD | 0.0% |
| 1994 Q4 | 6.5 Million USD | 983.33% |
| 1994 Q2 | 400 Thousand USD | 0.0% |
| 1994 Q3 | 600 Thousand USD | 50.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 98.138% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 53.302% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 30.755% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -34.002% |
| uniQure N.V. | 285.08 Million USD | 33.037% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 55.36% |
| bluebird bio, Inc. | 240.23 Million USD | 20.534% |
| Imunon, Inc. | 21.03 Million USD | -807.747% |
| Dynavax Technologies Corporation | 219.14 Million USD | 12.887% |
| Editas Medicine, Inc. | 247.3 Million USD | 22.806% |
| Illumina, Inc. | 3.81 Billion USD | 94.993% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 57.671% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 90.701% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 82.476% |
| Myriad Genetics, Inc. | 600.1 Million USD | 68.188% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 88.042% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 85.971% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 63.913% |
| Verastem, Inc. | 92.08 Million USD | -107.314% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 99.53% |
| Waters Corporation | 943.51 Million USD | 79.767% |
| Biogen Inc. | 5.2 Billion USD | 96.332% |
| Perrigo Company plc | 1.52 Billion USD | 87.51% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -1272.451% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -58.22% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -327.392% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 89.068% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 16.52% |
| Evolus, Inc. | 189.75 Million USD | -0.603% |
| Adicet Bio, Inc. | 152.03 Million USD | -25.563% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -1472.383% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 93.219% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 29.788% |
| FibroGen, Inc. | 398.11 Million USD | 52.048% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 90.974% |
| OPKO Health, Inc. | 574.68 Million USD | 66.781% |
| Homology Medicines, Inc. | 9.87 Million USD | -1833.195% |
| Geron Corporation | 70.44 Million USD | -171.011% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 89.395% |
| Exelixis, Inc. | 1.58 Billion USD | 87.969% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -89.337% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -242.39% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 65.389% |
| Zoetis Inc. | 2.76 Billion USD | 93.096% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 59.925% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -293.598% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 96.002% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -387.582% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 75.512% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 48.21% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 36.221% |
| Blueprint Medicines Corporation | 722.86 Million USD | 73.591% |
| Insmed Incorporated | 949.26 Million USD | 79.889% |
| TG Therapeutics, Inc. | 198.47 Million USD | 3.815% |
| Incyte Corporation | 1.19 Billion USD | 83.964% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 81.714% |